ALK-tyrosine kinase inhibitor intrinsic resistance due to
ALK-rearranged non-small cell lung cancer (ALK-rearranged NSCLC)
De novo MET-amplification
case report
intrinsic ALK-tyrosine kinase inhibitor resistance (intrinsic ALK-TKI resistance)
tyrosine kinase inhibitor combination (TKI combination)
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
20
05
2024
accepted:
26
07
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
21
10
2024
Statut:
ppublish
Résumé
Most patients with advanced anaplastic lymphoma kinase ( A 43-year-old, female diagnosed with T4N3M1c NSCLC harboring the echinoderm microtubule-associated protein-like 4 ( The combination of alectinib and crizotinib may be a feasible and effective treatment for
Sections du résumé
Background
UNASSIGNED
Most patients with advanced anaplastic lymphoma kinase (
Case Description
UNASSIGNED
A 43-year-old, female diagnosed with T4N3M1c NSCLC harboring the echinoderm microtubule-associated protein-like 4 (
Conclusions
UNASSIGNED
The combination of alectinib and crizotinib may be a feasible and effective treatment for
Identifiants
pubmed: 39430327
doi: 10.21037/tlcr-24-439
pii: tlcr-13-09-2453
pmc: PMC11484720
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
2453-2462Informations de copyright
2024 AME Publishing Company. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-439/coif). E.M.U. reports research grants from AstraZeneca and Merck; speaker fees from Amgen, AstraZeneca, Janssen and Novartis; travel support related to participation in international scientific meeting from AstraZeneca and Roche; payment for participation in Advisory Board from AstraZeneca, Pfizer, Roche and Takeda. M.G. reports speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim and ThermoFisher Scientific, and received research grants from Merck and Roche. J.B.S. received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, Janssen, Roche; received honoraria for lectures from Bristol-Myers Squibb, Janssen; received support for attending meetings and/or travel from AstraZeneca, Janssen, Merck; and received payment for participation in Advisory Board from AstraZeneca, Bristol-Myers Squibb, Genmab, Janssen, Merck, Roche. E.S.R. received research grants from Sanofi and Takeda; reports honoraria for lectures from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Roche, Takeda; and received payment for participation in Advisory Board from Roche and Takeda. The other authors have no conflicts of interest to declare.